Vol. 4 No. 7 (2024)
Reimbursement Reviews

Inebilizumab (Uplizna)

decorative image of the issue cover

Published July 22, 2024

Key Messages

  • Reimbursement reviews are comprehensive assessments of the clinical effectiveness and cost-effectiveness, as well as patient and clinician perspectives, of a drug or drug class.
  • The assessments inform non-binding recommendations that help guide the reimbursement decisions of Canada’s federal, provincial, and territorial governments, with the exception of Quebec.
  • This review assesses inebilizumab (Uplizna), 10 mg/mL, single-dose vials containing 100 mg inebilizumab in 10 mL solution, IV infusion.
  • Indication: As monotherapy for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are seropositive for anti-aquaporin-4 immunoglobulin G (AQP4-IgG). Treatment should be administered under the supervision of a qualified healthcare professional.